Milan is a PhD student in his last year of study at the University of Otago – Christchurch. His PhD project is focused on evaluating and optimising digital clinical decision support tools in hospital to promote medication safety. Milan is interested in harnessing the large volumes of routinely collected healthcare data in hospitals to inform and improve medicine use. As a current student, Milan is part of the ASCEPT student forum committee and the organising committee for the ASCEPT New Zealand forum

Dr. Chung-Ping Liao received his PhD from Indiana University School of Medicine and completed postdoctoral training at the University of Texas Southwestern Medical Center. Dr. Liao is currently an Associate Professor at the Graduate Institute of Medical Sciences, Taipei Medical University in Taiwan. His research focuses on the pathogenic mechanisms of tumors associated with the human genetic disorder neurofibromatosis type 1 (NF1). By leveraging comprehensive genetic mouse models, his study has identified the critical contributions of the immune microenvironment to neurofibroma tumorigenesis. His research group is also interested in the vulnerability of malignant peripheral nerve sheath tumors (MPNST) by targeting their epigenetic regulations. The ultimate goal of the Liao lab is to identify novel therapeutics for NF1 treatment.

Evan Browne is a Clinical Pharmacology, Toxicology and Nephrology Advanced Trainee based in Sydney with an interest in equity of care and the quality use of medicines.

Toni is a PhD student at the University of Sydney, School of Pharmacy. Her research is focused on understanding factors which contribute to the variability in urate response to gout medications and ovarian response to IVF medications (supervised by Dr. Sophie Stocker). She has received two awards for oral conference presentations.

Dr. Chariyavilaskul received her first degree as a Medical Doctor with honours from the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, in 2001. She underwent post-graduate training and received an M.Sc. in Clinical Pharmacology with Distinction from the University of Glasgow, Glasgow, UK, in 2004 and a Ph.D. in Medical Science from the University of Edinburgh, Edinburgh, UK in 2010. Dr. Charivavilaskul is currently an Associate Professor of Pharmacology and an Assistant Dean of Research Affairs, Faculty of Medicine, Chulalongkorn University. She is also the Head of Center of Excellence in Clinical Pharmacokinetics and Pharmacogenomics, the Head of Pharmacogenetics Laboratory Services, Center for Medical Diagnostic Laboratories, and an executive member of the Advisory Board of the Maha Chakri Sirindhorn Clinical Research Centre under the Royal Patronage, Faculty of Medicine, Chulalongkorn University. She is responsible for teaching pharmacology in both undergraduate and postgraduate training programs of the Faculty of Medicine. She is also an active researcher, focusing on the areas of clinical pharmacokinetics, pharmacodynamics, and pharmacogenomics.

Ramya is a PhD candidate at the University of Sydney in the Faculty of Medicine and Health. With a Masters in Bio-Technology, her prior experience of working in the drug discovery and pharmacovigilance field has inculcated a passion for Pharmacoepidemiology and drug safety. Her research utilises population-based health data to generate real-world evidence on medicine use and safety in the mental health space. She has further undergone training in Epidemiological methods and Health economic evaluations. Ramya’s PhD is focussed on the investigation of cardiometabolic adverse effects associated with antipsychotic treatments given at low doses in off-label disorders, using Australian administrative datasets. Her aim is to improve patient health and well-being through the quality use of medicines.